Ionis Pharmaceuticals (IONS) Enterprise Value (2009 - 2026)

Ionis Pharmaceuticals' Enterprise Value history runs 18 years deep, the most recent figure standing at -$1.9 billion for Q1 2026.

• On a quarterly basis, Enterprise Value rose 10.54% year-over-year to -$1.9 billion in Q1 2026; TTM through Mar 2026 was -$1.9 billion, a 10.54% increase from a year earlier, with the FY2025 full-year figure at -$2.7 billion, down 16.53% from the prior year.
• Enterprise Value grew to -$1.9 billion in Q1 2026 per IONS's latest filing, from -$2.7 billion in the prior quarter.
• Across five years, Enterprise Value topped out at -$1.9 billion in Q1 2026 and bottomed at -$2.7 billion in Q4 2025.
• The 5-year median for Enterprise Value is -$2.2 billion (2023), against an average of -$2.2 billion.
• Across the five-year window, Enterprise Value decreased 17.98% in 2023 and increased 12.86% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$2.0 billion in 2022, then slipped by 17.33% to -$2.3 billion in 2023, then advanced by 1.44% to -$2.3 billion in 2024, then fell by 16.53% to -$2.7 billion in 2025, then increased by 28.32% to -$1.9 billion in 2026.
• Per Business Quant, the three latest IONS Enterprise Value figures stand at -$1.9 billion (Q1 2026), -$2.7 billion (Q4 2025), and -$2.2 billion (Q3 2025).